NASDAQ:HPTX »
-
Company News » Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hyperion Therapeutics, Inc. StockholdersBusiness Wire - September 10, 2014, 22:57 GMTKirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data. On September 8, 2014, the Company announced that it is terminating development of DiaPep277 for
-
Company News » EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Hyperion Therapeutics, Inc. — HPTXBusiness Wire - September 8, 2014, 17:39 GMT
The Rosen Law Firm, P.A. announces that it is investigating potential securities claims against Hyperion Therapeutics, Inc. (NASDAQ:HPTX) resulting from allegations that the Company may have issued materially false statements to investors. On September 8, 2014, Hyperion Therapeutics shocked the market when it announced that it would terminate the development of its diabetes drug, DiaPep277,
| Forex Broker Spreads » |
|
Iron FX
XM Markets
FxPro
FXCM| Most Popular Articles » |
- Western Union Offers Apple PayTM as New Pay-In Option for Money Transfer Customers 2 views
- US Dollar Still Vulnerable to Durable Goods 1 view
- Stocks Close Mixed; Service Sector Under Pressure 1 view
- IMS Health’s Social Media Analytics Solution Named a Leader by IDC MarketScape 1 view
- Harman to Collaborate with Pono and Neil Young to Bring Pono HD Music into the Car 1 view
- Euro Trades Defensively with FOMC Waiting in the Wings 1 view
- Sir Hector Sants to Join Oliver Wyman 1 view
- Bank of England Quarterly Inflation Report 1 view
- Cancer and pregnancy top reasons for using disability insurance benefits, Unum says 1 view
- Stocks Tumble as Brinkmanship Continues 1 view